A number of research firms have changed their ratings and price targets for Werewolf Therapeutics (NASDAQ: HOWL): 6/4/2024 – Werewolf Therapeutics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock. 6/3/2024 – Werewolf Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. […]
Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) was the target of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 372,000 shares, a drop of 10.3% from the April 30th total of 414,500 shares. Based on an average daily volume of 185,300 shares, […]
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
HC Wainwright restated their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a research report released on Friday morning, Benzinga reports. The firm currently has a $15.00 price objective on the stock. Other equities analysts have also recently issued research reports about the stock. Wedbush reiterated an outperform rating and issued […]